BNT162a1 SARS-CoV-2 Vaccine
BNT162a1 SARS-CoV-2 Vaccine Uses, Dosage, Side Effects, Food Interaction and all others data.
BNT162a1 is one of four advanced mRNA-based vaccines being developed through "Project Lightspeed," a joint program between Pfizer and BioNTech. BNT162a1 is a uridine mRNA (uRNA) vaccine formulated in lipid nanoparticles for delivery via intramuscular injection.
BNT162a1 is undergoing evaluation in clinical trials in both the USA (NCT04368728) and Germany (NCT04380701).
Trade Name | BNT162a1 SARS-CoV-2 Vaccine |
Generic | BNT162a1 SARS-CoV-2 Vaccine |
Type | |
Groups | Investigational |
Therapeutic Class | |
Manufacturer | |
Available Country | |
Last Updated: | September 19, 2023 at 7:00 am |
Innovators Monograph
You find simplified version here BNT162a1 SARS-CoV-2 Vaccine